X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (571) 571
Book Review (73) 73
Conference Proceeding (50) 50
Publication (35) 35
Book Chapter (7) 7
Patent (7) 7
Book / eBook (3) 3
Web Resource (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (272) 272
humans (250) 250
melanoma (250) 250
oncology (223) 223
cancer (136) 136
immunotherapy (120) 120
female (116) 116
male (110) 110
melanoma - drug therapy (105) 105
middle aged (98) 98
ipilimumab (92) 92
aged (89) 89
metastatic melanoma (89) 89
metastasis (88) 88
melanoma - pathology (86) 86
care and treatment (85) 85
adult (84) 84
survival (76) 76
research (72) 72
medicine (69) 69
medicine, research & experimental (68) 68
mutation (67) 67
melanoma - genetics (66) 66
tumors (57) 57
skin neoplasms - drug therapy (56) 56
skin neoplasms - pathology (52) 52
aged, 80 and over (51) 51
analysis (50) 50
biochemistry, genetics and molecular biology (49) 49
immunology (49) 49
proto-oncogene proteins b-raf - genetics (48) 48
vemurafenib (48) 48
patients (47) 47
antineoplastic agents - therapeutic use (46) 46
treatment outcome (46) 46
prognosis (45) 45
drug therapy (42) 42
chemotherapy (41) 41
clinical trials (41) 41
health aspects (41) 41
cutaneous melanoma (40) 40
neoplasm staging (40) 40
disease-free survival (39) 39
open-label (39) 39
metastases (38) 38
therapy (38) 38
medical research (37) 37
cancer therapies (36) 36
nivolumab (36) 36
antibodies, monoclonal - therapeutic use (33) 33
development and progression (33) 33
hematology, oncology and palliative medicine (31) 31
melanoma - mortality (31) 31
italy (30) 30
skin neoplasms - genetics (30) 30
young adult (30) 30
genetic aspects (29) 29
malignant-melanoma (29) 29
skin cancer (29) 29
braf (28) 28
safety (28) 28
animals (27) 27
kinases (27) 27
melanoma - immunology (27) 27
biomarkers (26) 26
neoplasms - therapy (26) 26
proto-oncogene proteins b-raf - antagonists & inhibitors (26) 26
dabrafenib (25) 25
gene mutations (25) 25
melanoma - metabolism (25) 25
neoplasms - immunology (25) 25
antineoplastic agents - adverse effects (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
cancer research (23) 23
dermatology (23) 23
multicenter (23) 23
studies (23) 23
usage (23) 23
adolescent (22) 22
cell line, tumor (22) 22
pembrolizumab (22) 22
phase-ii (22) 22
review (22) 22
gene expression (21) 21
kaplan-meier estimate (21) 21
diagnosis (20) 20
patient outcomes (20) 20
skin neoplasms - mortality (20) 20
antineoplastic agents (19) 19
disease progression (19) 19
immunohistochemistry (19) 19
medicine & public health (19) 19
melanoma - therapy (19) 19
risk factors (19) 19
immunotherapy - methods (18) 18
medicine, experimental (18) 18
meeting report (18) 18
mek inhibitors (18) 18
melanoma - secondary (18) 18
neoplasm metastasis (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Translational Medicine, ISSN 1479-5876, 12/2019, Volume 17, Issue 1, pp. 1 - 11
The great debate session at the 2018 Melanoma Bridge congress (November 29–December 1, Naples, Italy) featured counterpoint views from experts on three topical... 
Congress | Medical research | Antigens | Melanoma | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Gene expression | Patients | Cancer therapies | Quality of life | Immunotherapy | Drug dosages | BRAF inhibitor | Anti-PD-1 | Targeted therapy | Anti-CTLA-4
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2015, Volume 14, Issue 12 Supplement 2, pp. PL02-01 - PL02-01
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 01/2019, Volume 68, Issue 1, pp. 97 - 107
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 07/2015, Volume 13, Issue 1, pp. 213 - 213
Journal Article
2015, 1st ed. 2015., Cancer Drug Discovery and Development, ISBN 3319211668
This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of... 
Medicine | Cancer research | Immunology | Cell biology | Molecular biology
Web Resource
2015, 1st ed. 2015., Cancer Drug Discovery and Development, ISBN 3319211668
This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of... 
Medicine | Cancer research | Immunology | Cell biology | Molecular biology
Web Resource
2015, 1st ed. 2015, Cancer Drug Discovery and Development, ISBN 3319211668, 315
This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of... 
Clinical & internal medicine | Cytology | Cancer Research | Molecular Medicine | Biomedicine | Immunology | Cell Biology | T cells | Cancer
eBook
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 45 - 55
We conducted a retrospective analysis to evaluate the impact of concomitant acid-reducing agents (ARAs) and vemurafenib dose on the efficacy of vemurafenib in... 
Vemurafenib | Cobimetinib | Acid-reducing agents | Drug interactions | Melanoma | Dosing | Effectiveness | Acids | Reducing agents | Metastasis | Mutation | Survival | Steady state | Subgroups | Metastases
Journal Article
The Journal of Molecular Diagnostics, ISSN 1525-1578, 09/2019, Volume 21, Issue 5, pp. 756 - 767
An enduring goal of personalized medicine in cancer is the ability to identify patients who are likely to respond to specific therapies. Our growing... 
Journal Article
Cancer, ISSN 0008-543X, 06/2014, Volume 120, Issue 11, pp. 1617 - 1619
Journal Article
BMC CANCER, ISSN 1471-2407, 08/2019, Volume 19, Issue 1, pp. 772 - 772
Introduction Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several... 
SURVIVAL | Mutations | CDKN2A MUTATIONS | SINGLE | CDKN2A | Melanoma | SUSCEPTIBILITY | RISK | BRAF | POPULATION-BASED PREVALENCE | MALIGNANT-MELANOMA | FEATURES | ONCOLOGY | FAMILIES | Skin | NGS | MC1R VARIANTS | Cancer | Usage | Gene mutations | Physiological aspects | Genetic aspects | Research | Diagnosis | Nucleotide sequencing | Risk factors | DNA sequencing | Index Medicus
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 3/2015, Volume 64, Issue 3, pp. 271 - 274
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 883 - 895
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 01/2012, Volume 10, Issue 1, pp. 1 - 1
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article